MedTrace Logo

South Africa Smoking Cessation and Engagement in HIV/TB Care Care

NCT05842161 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-04-06

No results posted yet for this study

Summary

The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings.

Conditions

Interventions

BEHAVIORAL

QUIT-AD

An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence

OTHER

Enhanced Treatment as Usual

Standard treatment for HIV/TB with one session of psychoeducation.

Sponsors & Collaborators

  • Boston University

    collaborator OTHER

  • University of Cape Town

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Amelia Stanton, PhD · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-12
Primary Completion
2026-05-01
Completion
2026-05-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05842161 on ClinicalTrials.gov